IBDEI1MH ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27525,1,4,0)
 ;;=4^N04.8
 ;;^UTILITY(U,$J,358.3,27525,2)
 ;;=^5015539
 ;;^UTILITY(U,$J,358.3,27526,0)
 ;;=N04.9^^106^1363^62
 ;;^UTILITY(U,$J,358.3,27526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27526,1,3,0)
 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
 ;;^UTILITY(U,$J,358.3,27526,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,27526,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,27527,0)
 ;;=N05.0^^106^1363^50
 ;;^UTILITY(U,$J,358.3,27527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27527,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,27527,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,27527,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,27528,0)
 ;;=N05.1^^106^1363^49
 ;;^UTILITY(U,$J,358.3,27528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27528,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,27528,1,4,0)
 ;;=4^N05.1
 ;;^UTILITY(U,$J,358.3,27528,2)
 ;;=^5015542
 ;;^UTILITY(U,$J,358.3,27529,0)
 ;;=N05.2^^106^1363^46
 ;;^UTILITY(U,$J,358.3,27529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27529,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,27529,1,4,0)
 ;;=4^N05.2
 ;;^UTILITY(U,$J,358.3,27529,2)
 ;;=^5015543
 ;;^UTILITY(U,$J,358.3,27530,0)
 ;;=N05.3^^106^1363^47
 ;;^UTILITY(U,$J,358.3,27530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27530,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27530,1,4,0)
 ;;=4^N05.3
 ;;^UTILITY(U,$J,358.3,27530,2)
 ;;=^5015544
 ;;^UTILITY(U,$J,358.3,27531,0)
 ;;=N05.4^^106^1363^45
 ;;^UTILITY(U,$J,358.3,27531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27531,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27531,1,4,0)
 ;;=4^N05.4
 ;;^UTILITY(U,$J,358.3,27531,2)
 ;;=^5015545
 ;;^UTILITY(U,$J,358.3,27532,0)
 ;;=N05.5^^106^1363^48
 ;;^UTILITY(U,$J,358.3,27532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27532,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,27532,1,4,0)
 ;;=4^N05.5
 ;;^UTILITY(U,$J,358.3,27532,2)
 ;;=^5015546
 ;;^UTILITY(U,$J,358.3,27533,0)
 ;;=N05.6^^106^1363^43
 ;;^UTILITY(U,$J,358.3,27533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27533,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,27533,1,4,0)
 ;;=4^N05.6
 ;;^UTILITY(U,$J,358.3,27533,2)
 ;;=^5015547
 ;;^UTILITY(U,$J,358.3,27534,0)
 ;;=N05.7^^106^1363^44
 ;;^UTILITY(U,$J,358.3,27534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27534,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,27534,1,4,0)
 ;;=4^N05.7
 ;;^UTILITY(U,$J,358.3,27534,2)
 ;;=^5015548
 ;;^UTILITY(U,$J,358.3,27535,0)
 ;;=N05.8^^106^1363^51
 ;;^UTILITY(U,$J,358.3,27535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27535,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,27535,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,27535,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,27536,0)
 ;;=N05.9^^106^1363^52
 ;;^UTILITY(U,$J,358.3,27536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27536,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ unspec morphologic changes
 ;;^UTILITY(U,$J,358.3,27536,1,4,0)
 ;;=4^N05.9
 ;;^UTILITY(U,$J,358.3,27536,2)
 ;;=^5134086
 ;;^UTILITY(U,$J,358.3,27537,0)
 ;;=N06.0^^106^1363^40
 ;;^UTILITY(U,$J,358.3,27537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27537,1,3,0)
 ;;=3^Isolated proteinuria w/ minor glomerular abnormality
